Interim report January-March 2014: Strengthened operating

First quarter in brief:

  · Sales growth was 12 percent in local currency. Sales amounted to SEK 119
(105) million, corresponding to an increase of 14 percent in SEK.
  · Operating income (EBIT) amounted to SEK 30 (17) million, corresponding to an
operating margin of 25 (16) percent. Operating income included a recovered
additional purchase price of SEK 2 million regarding the acquisition of Cryo
Management Ltd. Adjusted for this, the operating margin amounted to 23 (16)
percent.
  · Net income amounted to SEK 22 (12) million, which gave earnings per share of
SEK 1.12 (0.60).

Gothenburg, April 23, 2014

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
23, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January-March 2014: Strengthened operating margin

Attachments
